Back to Live Wire
business2 min read16h ago

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

CNBCNewswireFriday, May 29, 2026
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Read Full Article at CNBCTrack More Signals

Desk Brief

Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.

Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.

Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.

This article is sourced from CNBC. For the complete story, analysis, and additional context, read the full article.